IOB - Delayed Quote EUR

Ercros, S.A. (0M0E.IL)

Compare
3.5300 +0.0025 (+0.07%)
At close: November 21 at 2:35 PM GMT
Loading Chart for 0M0E.IL
DELL
  • Previous Close 3.5275
  • Open 0.0000
  • Bid 3.4550 x --
  • Ask 3.6300 x --
  • Day's Range 3.5300 - 3.5300
  • 52 Week Range 2.2700 - 3.9650
  • Volume 813
  • Avg. Volume 49
  • Market Cap (intraday) 343.907M
  • Beta (5Y Monthly) 1.01
  • PE Ratio (TTM) 8.82
  • EPS (TTM) 0.4000
  • Earnings Date Nov 15, 2024
  • Forward Dividend & Yield 0.15 (5.31%)
  • Ex-Dividend Date Jun 26, 2023
  • 1y Target Est --

Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding compunds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing of particle, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; sockets and switches in the electrical components sector; and tableware, and health and packaging items in the textile tanning industry. The Pharmacy division engages in the production of raw materials and pharmaceutical intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, fosfomycin calcium and sodium, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

www.ercros.es

1,343

Full Time Employees

December 31

Fiscal Year Ends

Chemicals

Industry

Recent News: 0M0E.IL

View More

Performance Overview: 0M0E.IL

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0M0E.IL
34.51%
IBEX 35...
15.39%

1-Year Return

0M0E.IL
43.15%
IBEX 35...
18.61%

3-Year Return

0M0E.IL
20.68%
IBEX 35...
33.17%

5-Year Return

0M0E.IL
76.50%
IBEX 35...
26.51%

Compare To: 0M0E.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0M0E.IL

View More

Valuation Measures

Annual
As of 11/22/2024
  • Market Cap

    323.23M

  • Enterprise Value

    439.86M

  • Trailing P/E

    25.34

  • Forward P/E

    14.10

  • PEG Ratio (5yr expected)

    0.31

  • Price/Sales (ttm)

    0.50

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    0.69

  • Enterprise Value/EBITDA

    20.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.66%

  • Return on Assets (ttm)

    3.88%

  • Return on Equity (ttm)

    10.77%

  • Revenue (ttm)

    909.25M

  • Net Income Avi to Common (ttm)

    38.11M

  • Diluted EPS (ttm)

    0.4000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.63M

  • Total Debt/Equity (mrq)

    40.42%

  • Levered Free Cash Flow (ttm)

    -11.39M

Research Analysis: 0M0E.IL

View More

Company Insights: 0M0E.IL

Research Reports: 0M0E.IL

View More

People Also Watch